ANI Pharmaceuticals Inc. is a diversified biopharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals. It specializes in a range of dosage forms, including liquid, powder, oral solid-dose products, injectables, softgel capsules, semi-solids, topicals, and controlled substances. The company operates through key segments: Rare Disease, featuring novel therapeutics in ophthalmology, rheumatology, nephrology, neurology, and pulmonology, such as Purified Cortrophin Gel, ILUVIEN, and YUTIQ; Generics, leveraging R&D expertise and U.S.-based manufacturing for products like Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone, and Vancomycin; and Established Brands. ANI Pharmaceuticals Inc. focuses on areas like narcotics, oncolytics, hormones, steroids, and complex formulations including extended-release and combination products. Primarily serving the United States and Canada, it emphasizes high-quality therapeutics through operational excellence and North American manufacturing capabilities. Founded in 2001 and headquartered in Baudette, Minnesota, ANI Pharmaceuticals Inc. plays a vital role in addressing patient needs across specialized pharmaceutical markets.